{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-017392","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.385946+00:00","generated_at":"2026-06-23T23:52:33.339519+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Athira reports Q2 net loss $24.3M; ACT-AD Phase 2 Alzheimer's trial missed primary endpoint","bullets":["Net loss $24.3M ($0.65/share) vs $14.0M ($0.38/share) in Q2 2021; cash $282.2M.","ACT-AD Phase 2 trial of fosgonimeton did not meet primary endpoint (P300 latency).","Monotherapy subgroup showed ADAS-Cog11 improvement of -3.3 points vs placebo (not significant).","Statistically significant reduction in plasma NfL biomarker in monotherapy subgroup (p=0.018).","LIFT-AD Phase 3 enrollment ongoing; over 300 patients enrolled as of report date."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-017392","json":"https://secwatch.observer/filing/0000950170-22-017392.json","markdown":"https://secwatch.observer/filing/0000950170-22-017392.md","text":"https://secwatch.observer/filing/0000950170-22-017392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022017392/0000950170-22-017392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022017392/atha-20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:52:33.339519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}